Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CLL1 CAR-T in Relapsed/Refractory AML
NCT07432100Phase 1Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of universal CLL1 CAR-T cells in acute myeloid leukemia (AML). Primary endpoints: Bone marrow tumor burden at 24 months, Overall Survival up to 60 months and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
universal CLL1 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07432100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432100.